SK바이오사이언스

302440KOSPI기초 의약물질 제조업

47.8 / 100

Reference Date: 2026-06-10

Financial Score14.5 / 40

News Sentiment18.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Declined 7.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bioscience, established in 2018 as a spin-off from SK Chemicals, focuses on vaccine development and global CDMO services. Key products include cell-culture influenza vaccines like 'SkyCellflu' and the COVID-19 vaccine 'SkyCovion,' which received WHO PQ certification and global approvals. The company also provides CDMO services, collaborating with global pharmaceutical firms to produce and develop vaccines.

Number of Employees

1,129people

Average Salary

67.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

1.50Industry Average 1.744.0Point

In line with industry avg

ROE

-2.77Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

29.06Industry Average 6.620.0Point

4.4x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲57.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼522.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.4% (declining, 3yr)

Detailed News Sentiment

30 totalPositive 20Neutral 8Negative 2Average Sentiment Score 73.3

Positive
SK바이오사이언스, 주사형 로타백신 개발 나선다
SK바이오사이언스가 CDC의 로타백신 기술 도입을 통해 주사형 백신 개발에 진출함으로써 기술적 우위와 시장 경쟁력 강화가 예상된다.
Positive
SK바사, 美 CDC와 19조 '로타바이러스' 백신 시장 정조준
SK바이오사이언스가 미국 CDC로부터 로타바이러스 백신 후보물질을 확보하여 상용화 가능성을 높이고 있어 긍정적인 시장 전망을 이끌고 있다.
Positive
"연내 AI 에이전트 100개 운영 계획…백신 개발기간 30%이상 앞당...
SK바이오사이언스의 AI 기술 도입으로 백신 개발 기간이 크게 단축되어 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 39,000Won52-week high 60,10052-week low 39,000

1-month return1.0Point

1m -7.14% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업지배구조보고서공시2026-05-29
Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-05-29
Neutral분기보고서 (2026.03)2026-05-13